Returning search results with filters:
Remove filter forAudience: Healthcare
Remove filter forIssue: New safety information
Remove filter forIssue: Product withdrawal Clear all
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 3 of 3 items.
IDHIFA (enasidenib mesylate) – Market Withdrawal and Continued Access
IDHIFA failed to demonstrate improved OS in adult patients with late stage AML and an IDH2 mutation versus conventional care regimens in a Phase 3 confirmatory study evaluating efficacy and safety. Do not initiate IDHIFA in new patients. IDHIFA is…
AlertHealth professional risk communication | 2023-06-08
ISTODAX (romidepsin) – Restricted Access Program
In 2013, ISTODAX (romidepsin) was authorized under a Notice of Compliance with conditions (NOC/c) for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant and have received at least one…
AlertHealth professional risk communication | 2023-03-20
RUZURGI (amifampridine) - Authorization Status
UPDATED INFORMATION – January 20, 2023 On January 10, 2023, following a Federal Court of Appeal decision, the June 24, 2021 decision of the Minister of Health on the application of the data protection provisions was restored, and a new Notice of…
AlertHealth professional risk communication | 2023-01-20